Company intelligence / Profile preview

Renatus

Daejeon, Daejeon, South Koreamyrenatus.com ↗

Ownership: Private
Development stage: Other

Overview

Renatus has developed a proprietary technology to normalize cellular cholesterol levels using novel cyclodextrins and small molecules. Their lead candidate, RN-005, has shown efficacy in preclinical models of chronic kidney disease. The company holds patents for its approach and was selected for several biotech innovation programs/grants. No human clinical data reported as of June 2025.

Therapeutic areas: NeurologyCardiovascularNephrology
Modalities: Small moleculeCyclodextrin-based therapy
Industry: Biotech

Drug pipeline

1 asset

RN-005

Preclinical

Partnerships

CarbohydeMerckKHIDI Hospital-Based Business Innovation CenterIncheon Startup Park Scale-Up Challenge LabMinistry of SMEs & Startups Startup-Focused University Program

Beyond the preview

Go deeper on Renatus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Renatus.

Explore the full profile